key: cord-0773578-f00bpvmt
authors: Williams, Vonetta M.; Kahn, Jenna M.; Harkenrider, Matthew M.; Chino, Junzo; Chen, Jonathan; Fang, L. Christine; Dunn, Emily F.; Fields, Emma; Mayadev, Jyoti S.; Rengan, Ramesh; Petereit, Daniel; Dyer, Brandon A.
title: COVID-19 Impact on Timing of Brachytherapy Treatment and Strategies for Risk Mitigation
date: 2020-04-21
journal: Brachytherapy
DOI: 10.1016/j.brachy.2020.04.005
sha: 8c68f4e44c376bfed65b3c5ed4a7d99f6ccf9522
doc_id: 773578
cord_uid: f00bpvmt

PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve.

The novel SARS-CoV-2 (Severe Acute Respiratory Syndrome Corona Virus 2) causing COronaVIrus 32 has resulted in a global pandemic with unprecedented impact on medical 33 resources and personnel, and patient care access issues. Given the ease of host-host transmission and 34 impact on medical resources much of the world has implemented physical distancing and restrictions on 35 when it is appropriate to leave home to further reduce transmission and subsequent strain on medical 36 resources. There is some suggestion that patients with cancer and COVID-19 may have worse respiratory 37 outcomes than patients without cancer 1 ; however, these data are preliminary 2 . 38

Given the constantly evolving challenges surrounding COVID-19 and the potential impact on 39 healthcare, we reviewed amassing evidence to help guide the management and timing of brachytherapy 40 for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed 41 expert opinion is provided. Importantly, these recommendations apply only to patients not known to be 42 infected with SARS-CoV-2. For patients with symptoms concerning for COVID-19, or who have already 43 tested positive, we recommend following the local clinic and/or hospital treatment policies and 44 procedures given the unique resources of each institution. Delay of treatment until a negative COVID-19 45 test may be indicated in order to protect the patient, the treating team, and to maintain access to care 46 for all other patients treated at that facility. Given this, the purpose of the following commentary is to 47 seroma cavity, and therefore falls in line with timing of external beam. For patients with DCIS radiation 126 can be safely delayed up to 12 weeks following breast conserving surgery 27 . For patients with invasive 127 disease there is mixed data regarding timing of adjuvant treatment. Some studies show that RT 128 treatment delay of 8-12 weeks following BCS was associated with inferior local control 28 , and a large 129 systematic review of 46 studies showed local recurrence rates to be significantly higher in patients 130 receiving adjuvant RT more than 8 weeks after surgery compared with those treated within 8 weeks (OR 131 1.62, 95% CI 1. 21-2.16) 29 . Other studies have shown that intervals up to 20 weeks may be safe and 132 have no detriment to local control or overall survival (OS) for some patients without adverse tumor 133 control or survival outcomes [30] [31] [32] [33] [34] . 134

There is conflicting data regarding whether postponement of treatment after diagnosis leads to worse 136 outcomes in prostate cancer 35 , for both surgery [36] [37] [38] 40 . It is likely that the retrospective nature 137 of these studies and heterogeneous patient groups play a large role in the variability of findings. The 138 largest of these studies involving surgery examined 3,969 prostatectomy patients that underwent 139 surgery within one year of diagnosis 36 . It found no impact by time from biopsy to surgery on 140 biochemical recurrence after a mean follow-up of 5.4 years; this remained true even when they 141 examined the subset of higher risk patients. Similarly, the largest study on RT examined 1,322 patients 142 who underwent EBRT alone 39 . They found no difference in OS, cause-specific survival (CSS), Distant 143 metastasis (DM), or freedom from biochemical failure (FFBF) based on time to treatment (< 3, 3-6, 6-9, 144 or > 9 months after diagnosis). They also found no difference in FFBF or DM in high-risk patients. Based 145 on these studies, and others 41 , the safe interval of postponement until definitive treatment may be 6-12 146 months. Even if there is a true detriment in cancer outcomes with postponement of therapy that is not 147 fully captured by these studies. The conflicting data suggest a small magnitude that must be weighed 148 against the risks posed to patients and society during the COVID-19 pandemic.

Overall, it is unlikely that postponement of a few months is unlikely to significantly impact 150 disease outcomes. This is likely true for most grade group 1 and 2 cancers due to their more indolent 151 rate of growth, and for most higher-grade cancers due to the efficacy of androgen deprivation therapy 152 (ADT). Traditionally, two months of neoadjuvant ADT is given prior to RT, although recent evidence 153 suggests this is not necessary 42 . However, in the setting of COVID-19 and to attempt to reduce patient 154 exposure, neoadjuvant ADT may be given for as many as 6 months (and possibly longer) prior to 155 definitive therapy given the excellent and equivalent results seen in studies using this approach. 156

The use of brachytherapy in the treatment of prostate cancer is typically as definitive treatment 157 there is data to suggest that two fractions may result in decreased tumor control 54 . 215

For interstitial cervical HDR brachytherapy the ABS recommend a single implantation with five 216 treatments delivered twice daily with a minimum of 6 hours separation between fractions 50 . 217

Alternatively, if delivery of five or more fractions during a single hospitalization is not feasible, delivery 218 of 7 Gy twice per day separated by a 6 hour interval performed twice during two separate implantations 219 on consecutive weeks has also been found effective. Various fractionation options are shown in Table 1 .

For tumors with distal vaginal extension or involvement, smaller fraction sizes and additional fractions 221 may be necessary may minimize risk of high-grade toxicity and dose to organs at risk (OARs). 222

For early stage uterine cancer, adjuvant vaginal cuff monotherapy using HDR brachytherapy in three to 224 six fractions is common. In the setting of COVID-19, minimizing patient exposure risk is imperative. The 225 use of 7 Gy x 3 fractions to a depth dose of 0.5 cm is common and safe 56,57 . However, in selected 226 patients, such as those with anatomy requiring a cylinder size < 20 mm, consideration of a four to five 227 fraction regimen may help prevent excessive vaginal dose and late toxicity 57 Table 1 . 232

For women with breast cancer treated with breast conserving surgery, APBI is an option, Table 1 . Single-234 entry intracavitary devices will be easier to place at the time of surgery or within 4 weeks thereafter 235 while the surgical cavity/seroma can be identified. Multicatheter interstitial implantations do not strictly 236 rely on implantation into the surgical cavity and can therefore be performed immediately following 237 surgery, or later. The TRIUMPH-T trial of 7.5 Gy x 3 fraction APBI in women treated with breast 238 conserving surgery and tumors < 3 cm showed low toxicity with excellent cosmetic outcomes and good 239 local control. Other fractionation options include 34 Gy delivered in 10 fractions given twice per day as 240 on RTOG 9517 58 , or 32 Gy delivered in 8 fractions given twice per day 59 Gy x 2 fractions is preferred, and 19 Gy x 1 fraction is inferior 60 . While BT (definitive or boost) offers a 248 shorter overall treatment course than conventional or moderately hypofractionated EBRT, 249 brachytherapy practitioners should consider any resource limitations (access to personal protective 250 equipment, limited personnel, limited physical space, etc) that may prevent or delay BT delivery. Given 251 these considerations it should be noted that stereotactic ablative radiation (SABR) is a safe and effective 252 treatment for all patient risk categories and can be delivered in 5 or 7 fractions 61 . As with patients receiving general analgesia, an individualized anesthesia plan should be 266 developed, and a pre-procedural evaluation is required to better understand and minimize patient risks. 267

The ongoing involvement of anesthesiology is strongly encouraged, and their input will be valuable for 268 physicians without moderate sedation experience. Open communication with all team members is 269 necessary to minimize the risk of aerosolizing particles during the brachytherapy procedure. If, after review of patient-and case-specific factors, it is felt that intubation and ventilation is 277 necessary, strong consideration should be given to having only anesthesia staff in the room during 278 intubation and extubation. Awareness of the ventilator filter system is important -particularly the viral 279 filtration efficiency and use of a breathing system filter 78 . Strong consideration should be given to high-280 efficiency particulate air (HEPA) filter system between the ventilator system and the patient 79 , and 281 disconnection of the system which the patient is being ventilated should be avoided. Furthermore, 282 similar to patients with tuberculosis, consider implementing a wait period prior to staff re-entry into the 283 room following extubation; however, this has not been studied for coronavirus to our knowledge. 284

Finally, early reports show that patients with COVID-19 may experience endothelial damage 285 with severe coagulopathy and/or thromboembolism 80,81 . In such patients who also require 286 brachytherapy implantation with planned overnight hospitalization and immobilization, strong 287 consideration should be given to the need for therapeutic anticoagulation and/or augmentation of the 288 implantation technique as necessary. 289 planning. An MRI was then obtained with Smit sleeve in place with fusion of MRI to subsequent CT-359 based brachytherapy implant co-registered to the Smit sleeve 89 . A third strategy, "cognitive fusion,"

where the treating physician contours on a CT with applicator in place while directly referring to a pre-361 brachytherapy MRI, may also aid in defining an HRCTV in a time and resource efficient manner. 362

While integration of MRI is optimal and encouraged in the manners noted above, when logistical 363 barriers exist to prevent this (which may potentially worsen with COVID-19), CT based volumetric 364 brachytherapy planning remains a highly accessible method of both reducing toxicity and improving 365 disease control, when compared to film based (point A) planning 90 . 366

Temporizing options, such as endocrine therapy, exist for patients who wish to avoid traditional 368 treatment paradigms to decrease the risk of COVID-19. As endometrioid precancerous lesions arise from 369 the prolonged exposure of the endometrium to estrogen, progestins can act to inhibit endometrial 370 proliferation and are used in the management of low risk or surgically inoperable women with 371 endometrial cancer 91 . These agents can be continuously for 3-6 months with reassessment for response 372 every 6 months. If by 12 months there is not a complete response, definitive surgery should be pursued. For breast and/or prostate cancer, delay of definitive or adjuvant therapy may also be possible 382 using endocrine therapy temporizing measures. 383

Patients who have gynecologic, breast, and prostate cancers where temporizing therapy is not 385 available/appropriate and brachytherapy treatment is indicated should be considered "priority 1" -386 deemed critical for therapy and require services/treatment due to a clinical situation where delay or 387 omission of therapy will result in severe negative impact on the oncologic outcome or life expectancy. If 388 a delay is anticipated the treating physician should make alternative plans as early as possible and 389 consider referral, if necessary, to another facility equipped and staffed to deliver treatment with 390 minimal to no disruption in the treatment timeline. There are many potential reasons for treatment 391 delay beyond physician-centric issues, Table 2 . Impact of staff shortage, lack of social workers and 392 ancillary support (housing, transportation), socioeconomic factors (loss of job, housing, insurance) may 393 all play a role. 394 Table 2 Factors affecting timely delivery of treatment 1

Coordination of care among different sites 2

Multidisciplinary coordination of care 3

Poor patient navigation of system 4

Patient factors, i.e. -illness, socioeconomic challenges, transportation 5

Institution factors, i.e. -staffing shortage, equipment shortage, medication shortage 395 Table 2 . Factors affecting the timely delivery of treatment. Factors 4 and 5 will likely be of most concern 396 during the COVID-19 pandemic. 397

While all hospital services and personnel are impacted by COVID-19 it is important to recognize 398 strategies that may mitigate or lessen the impact, or delay treatment, Table 3 . 399

In line with these strategies, the ABS 95 and ASTRO 96 recently issued recommendations in the 400 setting of COVID-19, which are outlined in the sections above. While reduced patient exposure and 401 resource utilization is important during COVID-19, it is critical to maintain brachytherapy services for 402 patients. Furthermore, the use of brachytherapy may shorten treatment time and exposure for some 403 patients. 404 Table 3 Strategies to preserve cancer care and minimize risk 1 Use of altered fractionation schedules 2 Endocrine therapy as a temporizing measure for breast, prostate, and uterine cancer (as appropriate) 3

Eliminate or consolidate non-essential OR procedures 4 Modify general anesthesia protocols or switch to neuraxial sedation and/or moderate sedation with local analgesia 5

Streamline staffing to minimize personnel exposure 6

Incorporate telemedicine where feasible 405 

Cancer patients in SARS-CoV-2 infection: a nationwide analysis 417 in China

Risk of COVID-19 for cancer patients

The Effect of the Overall Treatment Time of Fractionated-420 Irradiation on the Tumor-Control Probability of a Human Soft-Tissue Sarcoma Xenograft in 421 Nude-Mice

The effect of treatment duration in the local control of 423 cervix cancer

The adverse effect of treatment prolongation in 425 cervical carcinoma

Overall Treatment Time in Advanced Cervical Carcinomas -a 427

Critical Parameter in Treatment Outcome

The Influence of Treatment Time on Outcome for 429

Squamous-Cell Cancer of the Uterine Cervix Treated with Radiation -a Patterns-of-Care Study

The effect of treatment time in locally advanced cervical 432 cancer in the era of concurrent chemoradiotherapy

Effect of tumor dose, volume and overall treatment time 434 on local control after radiochemotherapy including MRI guided brachytherapy of locally 435 advanced cervical cancer

Postoperative Radiation-Therapy for Surgically 437

Staged Endometrial Cancer -Impact of Time Factors (Overall Treatment Time and Surgery-to-438 Radiation Interval) on Outcome

Relationship between Interval from Surgery to 440 Radiotherapy and Local Recurrence Rate in Patients with Endometrioid-type Endometrial 441 Cancer: a Retrospective Mono-institutional Italian Study

Interval Between Hysterectomy and Start of 443

Radiation Treatment Is Predictive of Recurrence in Patients With Endometrial Carcinoma

Does Interval between 446 Hysterectomy and Start of Radiation Treatment Influence Survival in Early Stage Endometrial 447 Carcinoma? A National Cancer Database Analysis

A phase III trial of surgery with or without adjunctive 449 external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a 450 Gynecologic Oncology Group study

Surgery and postoperative radiotherapy versus 452 surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. 453 PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

Vaginal brachytherapy versus pelvic external beam 456 radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an 457 open-label, non-inferiority, randomised trial

American Brachytherapy Society recurrent carcinoma of 459 the endometrium task force patterns of care and review of the literature

Consensus statement for brachytherapy for the 462 treatment of medically inoperable endometrial cancer

American Brachytherapy Society consensus guidelines 464 for interstitial brachytherapy for vaginal cancer

Definitive radiation therapy for squamous cell 466 carcinoma of the vagina

Definitive Radiotherapy for Primary Squamous Cell 468 Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate 469

Brachytherapy Boost the Best Treatment? Experience of Two Italian Institutes

Society of Surgical Oncology-American Society for 472 Radiation Oncology

Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ

Lumpectomy plus tamoxifen with or without irradiation 476 in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343

Sequencing of Androgen-Deprivation Therapy With External-527

Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial

Androgen Suppression Combined with Elective Nodal and 530

Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for 531 a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost

External Beam Boost for High-and Intermediate-risk Prostate Cancer

Comparative analysis of prostate-specific antigen free 535 survival outcomes for patients with low, intermediate and high risk prostate cancer treatment 536 by radical therapy. Results from the Prostate Cancer Results Study Group

A randomized trial of pelvic 539 radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the 540 cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group 541 Study

Concurrent chemotherapy and pelvic radiation 543 therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery 544 in high-risk early-stage cancer of the cervix

Prospective Phase 2 Trial of Permanent Seed Implantation 546

Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and 547 Quality of Life Outcomes

Is supplemental external beam 549 radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable 550 intermediate-risk disease?

Is supplemental external beam radiation therapy 552 necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two 553 prospective randomized trials

Compendium of fractionation choices for 555 gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report

Long-term results of high-558 dose rate brachytherapy in cervix cancer using a small number of fractions

Two fractions of high-dose-rate brachytherapy in the 561 management of cervix cancer

A Comparative Analysis of Two Different Dose 564

Fractionation Regimens of High Dose Rate Intracavitary Brachytherapy in Treatment of 565 Carcinoma of Uterine Cervix: A Prospective Randomized Study

Radiobiological Analysis of Outcomes Using 568 External Beam Radiotherapy Plus High Dose-Rate Brachytherapy (4x7 Gy or 2x9 Gy) for Cervical 569 Cancer in a Multi-Institution Trial

Dose-effect relationship and risk factors for vaginal 571 stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally 572 advanced cervical cancer in the EMBRACE study

American Brachytherapy Society consensus guidelines 574 for adjuvant vaginal cuff brachytherapy after hysterectomy

Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review

Long-Term Cancer Outcomes From Study NRG 579

A Phase 2 Study of Accelerated Partial Breast Irradiation With 580

Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast Cancer

5-year results of accelerated partial breast irradiation 583 using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost 584 after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 585 a randomised, phase 3, non-inferiority trial

Prostate high dose-rate brachytherapy as monotherapy 587 for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II 588 clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy

Long-term results of high-594 dose rate brachytherapy in cervix cancer using a small number of fractions

The changing landscape of brachytherapy for cervical 597 cancer: a Canadian practice survey

A Comparative Analysis of Two Different Dose 599

Fractionation Regimens of High Dose Rate Intracavitary Brachytherapy in Treatment of 600 Carcinoma of Uterine Cervix: A Prospective Randomized Study

American Brachytherapy Society consensus 603 guidelines for locally advanced carcinoma of the cervix

Vaginal brachytherapy alone: an alternative to adjuvant whole 606 pelvis radiation for early stage endometrial cancer

High-dose-rate brachytherapy alone post-hysterectomy for 608 endometrial cancer

A novel low dose fractionation regimen for adjuvant 610 vaginal brachytherapy in early stage endometrioid endometrial cancer

NRG Oncology/RTOG 0921: A phase 2 study of 613 postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab 614 followed by carboplatin and paclitaxel for patients with endometrial cancer

A phase II study of intensity modulated radiation 617 therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy 618 oncology group trial 0418

Three-Fraction Accelerated Partial Breast Irradiation (APBI)

Delivered With Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-621 T Trial

Results of 15Gy HDR-BT boost plus EBRT in intermediate-623 risk prostate cancer: Analysis of over 500 patients

Anesthesia and Procedural Care for Brachytherapy

Handbook of Image-Guided Brachytherapy

Adjusting 627 the pH of lidocaine for reducing pain on injection

A controlled trial of pain on skin infiltration with local anaesthetics

Reduced pain when injecting lidocaine

Sodium bicarbonate attenuates pain on skin infiltration with 633 lidocaine, with or without epinephrine

Cortisol resistance 635 in man

Progesterone resistance

Clinical Characteristics of Coronavirus Disease 2019 in China. The 639 New England journal of medicine

ISTH interim guidance on recognition and management of 641 coagulopathy in COVID-19

Computed tomography versus 643 magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a 644 prospective trial and preliminary guidelines for standardized contours

The impact of 647 sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: 648 results of a prospective comparative trial

Clinical outcome of protocol based image (MRI) guided 650 adaptive brachytherapy combined with 3D conformal radiotherapy with or without 651 chemotherapy in patients with locally advanced cervical cancer

Early outcomes and impact of a hybrid IC/IS 654 applicator for a new MRI-based cervical brachytherapy program

Value of Magnetic Resonance Imaging Without or With 657

Applicator in Place for Target Definition in Cervix Cancer Brachytherapy

The use of MRI deformable image 660 registration for CT-based brachytherapy in locally advanced cervical cancer

Factors associated with deformation accuracy and modes of failure 663 for MRI-optimized cervical brachytherapy using deformable image registration

Implementing MRI-based target delineation for cervical 666 cancer treatment within a rapid workflow environment for image-guided brachytherapy: A 667 practical approach for centers without in-room MRI

Impact of 3D image-based PDR brachytherapy on 669 outcome of patients treated for cervix carcinoma in France: results of the French STIC 670 prospective study

Conservative Treatment With Medroxyprogesterone Acetate 672

Plus Levonorgestrel Intrauterine System for Early-Stage Endometrial Cancer in Young Women 673 Pilot Study

Oncologic and Reproductive outcomes with 675 progestin therapy in women with endometrial hyperplasia and grade 1 Adenocarcinoma: A 676 systematic review

Levonorgestrel-Releasing Intrauterine Systems 678

Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-679 Analysis

Multicenter phase II study of fertility-sparing treatment 681 with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young 682 women

Leading Through the Storm: Lessons from the Epicenter at Northwell Health

Radiation Oncology